The dynamic nature of the K-Ras/calmodulin complex can be altered by oncogenic mutations
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Previous studies have emphasized that perturbations of protein allosteric networks often arise from mutations.[102, 103]”
From An NMR portrait of functional and dysfunctional allosteric cooperativity in cAMP‐dependent protein kinase A (2023) · cites this paper as [103]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
RAS-targeted therapies: is the undruggable drugged?
Moore, A. R., Rosenberg, S. C., McCormick, F., & Malek, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0068-6 · Cited by 1,103
Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations
Hunter, J. C., Manandhar, A., Carrasco, M. A., Gurbani, D., Gondi, S., & Westover, K. D. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0203 · Cited by 786
Ras Conformational Ensembles, Allostery, and Signaling
Lu, S., Jang, H., Muratcioglu, S., Gursoy, A., Keskin, O., Nussinov, R., & Zhang, J. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00542 · Cited by 355
Self-citationTargeting RAS Membrane Association: Back to the Future for Anti-RAS Drug Discovery?
Cox, A. D., Der, C. J., & Philips, M. R. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3214 · Cited by 351
Rellos, P., Pike, A. C. W., Niesen, F. H., Salah, E., Lee, W. H., von Delft, F., & Knapp, S. (2010) · PLoS Biology · doi:10.1371/journal.pbio.1000426 · Cited by 279
K-Ras promotes tumorigenicity through suppression of non-canonical Wnt signaling
Wang, M.-T., Holderfield, M., Galeas, J., Delrosario, R., To, M. D., Balmain, A., & McCormick, F. (2015) · Cell · doi:10.1016/j.cell.2015.10.041 · Cited by 196
Shifman, J. M., Choi, M. H., Mihalas, S., Mayo, S. L., & Kennedy, M. B. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0606433103 · Cited by 143
Cespedes, M. V., Sancho, F. J., Guerrero, S., Parreno, M., Casanova, I., Pavon, M. A., Marcuello, E., Trias, M., Cascante, M., Capella, G., et al. (2006) · Carcinogenesis · doi:10.1093/carcin/bgl063 · Cited by 67
Zhou, Z.-W., Ambrogio, C., Bera, A. K., Li, Q., Li, X.-X., Li, L., Son, J., Gondi, S., Li, J., Campbell, E., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-0448 · Cited by 60
Research works printed but not linked: 51
- Chin, 2000, Calmodulin: a prototypical calcium sensor, Trends Cell Biol, 10, 322, 10.1016/S0962-8924(00)01800-6 · DOI · Paper page
- Villalobo, 2020, The role of calmodulin in tumor cell migration, invasiveness, and metastasis, Int J Mol Sci, 21, 10.3390/ijms21030765 · DOI
- Izadi, 2018, Direct effects of Ca(2+)/calmodulin on actin filament formation, Biochem Biophys Res Commun, 506, 355, 10.1016/j.bbrc.2018.07.159 · DOI
- Urrutia, 2019, The crossroad of ion channels and calmodulin in disease, Int J Mol Sci, 20, 10.3390/ijms20020400 · DOI
- Sengupta, 2009, EGFR juxtamembrane domain, membranes, and calmodulin: kinetics of their interaction, Biophys J, 96, 4887, 10.1016/j.bpj.2009.03.027 · DOI
- Springer, 2017, Interaction with adenylate cyclase toxin from Bordetella pertussis affects the metal binding properties of calmodulin, FEBS Open Bio, 7, 25, 10.1002/2211-5463.12138 · DOI
- Stateva, 2015, Ca2+/Calmodulin and apo-calmodulin both bind to and enhance the tyrosine kinase activity of c-src, PLoS One, 10, 10.1371/journal.pone.0128783 · DOI
- Peersen, 1997, Intermolecular tuning of calmodulin by target peptides and proteins: differential effects on Ca2+ binding and implications for kinase activation, Protein Sci, 6, 794, 10.1002/pro.5560060406 · DOI
- Lee, 1996, Rin, a neuron-specific and calmodulin-binding small G-protein, and Rit define a novel subfamily of ras proteins, J Neurosci, 16, 6784, 10.1523/JNEUROSCI.16-21-06784.1996 · DOI · Paper page
- Wang, 1997, Identification and characterization of a calmodulin-binding domain in Ral-A, a Ras-related GTP-binding protein purified from human erythrocyte membrane, J Biol Chem, 272, 16002, 10.1074/jbc.272.25.16002 · DOI · Paper page
- Elsaraj, 2008, Regulation of platelet Rac1 and Cdc42 activation through interaction with calmodulin, Biochim Biophys Acta, 1783, 770, 10.1016/j.bbamcr.2008.01.022 · DOI
- Tebar, 2020, Pleiotropic roles of calmodulin in the regulation of KRas and Rac1 GTPases: functional diversity in health and disease, Int J Mol Sci, 21, 10.3390/ijms21103680 · DOI
- Karachaliou, 2013, KRAS mutations in lung cancer, Clin Lung Canc, 14, 205
- Eser, 2014, Oncogenic KRAS signalling in pancreatic cancer, Br J Canc, 111, 817, 10.1038/bjc.2014.215 · DOI · Paper page
- De Roock, 2011, KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer, Lancet Oncol, 12, 594, 10.1016/S1470-2045(10)70209-6 · DOI · Paper page
- Villalonga, 2001, Calmodulin binds to K-Ras, but not to H- or N-Ras, and modulates its downstream signaling, Mol Cell Biol, 21, 7345, 10.1128/MCB.21.21.7345-7354.2001 · DOI · Paper page
- Lopez-Alcala, 2008, Identification of essential interacting elements in K-Ras/calmodulin binding and its role in K-Ras localization, J Biol Chem, 283, 10621, 10.1074/jbc.M706238200 · DOI · Paper page
- Abraham, 2009, The hypervariable region of K-Ras4B is responsible for its specific interactions with calmodulin, Biochemistry, 48, 7575, 10.1021/bi900769j · DOI · Paper page
- Wu, 2011, Both the C-terminal polylysine region and the farnesylation of K-RasB are important for its specific interaction with calmodulin, PLoS One, 6
- Agamasu, 2019, KRAS prenylation is required for bivalent binding with calmodulin in a nucleotide-independent manner, Biophys J, 116, 1049, 10.1016/j.bpj.2019.02.004 · DOI · Paper page
- Garrido, 2018, Modeling and subtleties of K-Ras and Calmodulin interaction, PLoS Comput Biol, 14, 10.1371/journal.pcbi.1006552 · DOI
- Jang, 2019, The structural basis of the farnesylated and methylated KRas4B interaction with calmodulin, Structure, 27, 1647, 10.1016/j.str.2019.08.009 · DOI
- Grant, 2020, Calmodulin disrupts plasma membrane localization of farnesylated KRAS4b by sequestering its lipid moiety, Sci Signal, 13, eaaz0344, 10.1126/scisignal.aaz0344 · DOI
- Sperlich, 2016, Regulation of K-Ras4B membrane binding by calmodulin, Biophys J, 111, 113, 10.1016/j.bpj.2016.05.042 · DOI
- Villalonga, 2002, Calmodulin prevents activation of Ras by PKC in 3T3 fibroblasts, J Biol Chem, 277, 37929, 10.1074/jbc.M202245200 · DOI · Paper page
- Cox, 2014, Drugging the undruggable RAS: mission possible?, Nat Rev Drug Discov, 13, 828, 10.1038/nrd4389 · DOI · Paper page
- Moore, 2020, Author Correction: RAS-targeted therapies: is the undruggable drugged?, Nat Rev Drug Discov, 19, 902, 10.1038/s41573-020-0089-1 · doi:10.1038/s41573-020-0089-1
- Prakash, 2019, Probing the conformational and energy landscapes of KRAS membrane orientation, J Phys Chem B, 123, 8644, 10.1021/acs.jpcb.9b05796 · DOI
- Parker, 2018, The K-ras, N-ras, and H-ras isoforms: unique conformational preferences and implications for targeting oncogenic mutants, Cold Spring Harb Perspect Med, 8, 10.1101/cshperspect.a031427 · DOI · Paper page
- Parker, 2018, K-ras populates conformational states differently from its isoform H-ras and oncogenic mutant K-RasG12D, Structure, 26, 810, 10.1016/j.str.2018.03.018 · DOI · Paper page
- Nussinov, 2021, Inhibition of nonfunctional ras, Cell Chem Biol, 28, 121, 10.1016/j.chembiol.2020.12.012 · DOI
- Bos, 2007, GEFs and GAPs: critical elements in the control of small G proteins, Cell, 129, 865, 10.1016/j.cell.2007.05.018 · DOI · Paper page
- Dudas, 2020, Nucleotide-specific autoinhibition of full-length K-Ras4B identified by extensive conformational sampling, Front Mol Biosci, 7, 145, 10.3389/fmolb.2020.00145 · DOI
- Jang, 2016, The higher level of complexity of K-Ras4B activation at the membrane, FASEB J, 30, 1643, 10.1096/fj.15-279091 · DOI · Paper page
- Forbes, 2008, The catalogue of somatic mutations in cancer (COSMIC), Curr Protoc Hum Genet, 10
- Zhang, 2017, Phosphorylation weakens but does not inhibit membrane binding and clustering of K-Ras4B, ACS Chem Biol, 12, 1703, 10.1021/acschembio.7b00165 · DOI · Paper page
- Alvarez-Moya, 2011, CaM interaction and Ser181 phosphorylation as new K-Ras signaling modulators, Small GTPases, 2, 99, 10.4161/sgtp.2.2.15555 · DOI
- Chavan, 2013, Application of reductive (1)(3)C-methylation of lysines to enhance the sensitivity of conventional NMR methods, Molecules, 18, 7103, 10.3390/molecules18067103 · DOI
- Agell, 2002, Modulation of the Ras/Raf/MEK/ERK pathway by Ca(2+), and calmodulin, Cell Signal, 14, 649, 10.1016/S0898-6568(02)00007-4 · DOI · Paper page
- Welman, 2000, Structure and function of the C-terminal hypervariable region of K-Ras4B in plasma membrane targetting and transformation, Oncogene, 19, 4582, 10.1038/sj.onc.1203818 · DOI
- Dharmaiah, 2016, Structural basis of recognition of farnesylated and methylated KRAS4b by PDEdelta, Proc Natl Acad Sci U S A, 113, E6766, 10.1073/pnas.1615316113 · DOI · Paper page
- Villalobo, 2018, The multifunctional role of phospho-calmodulin in pathophysiological processes, Biochem J, 475, 4011, 10.1042/BCJ20180755 · DOI
- Wang, 2020, Post-translational modification of KRAS: potential targets for cancer therapy, Acta Pharmacol Sin
- Bivona, 2006, PKC regulates a farnesyl-electrostatic switch on K-Ras that promotes its association with Bcl-XL on mitochondria and induces apoptosis, Mol Cell, 21, 481, 10.1016/j.molcel.2006.01.012 · DOI · Paper page
- Jang, 2015, Mechanisms of membrane binding of small GTPase K-Ras4B farnesylated hypervariable region, J Biol Chem, 290, 9465, 10.1074/jbc.M114.620724 · DOI · Paper page
- Alvarez-Moya, 2010, K-Ras4B phosphorylation at Ser181 is inhibited by calmodulin and modulates K-Ras activity and function, Oncogene, 29, 5911, 10.1038/onc.2010.298 · DOI
- Vatansever, 2020, Comparative effects of oncogenic mutations G12C, G12V, G13D, and Q61H on local conformations and dynamics of K-Ras, Comput Struct Biotechnol J, 18, 1000, 10.1016/j.csbj.2020.04.003 · DOI
- Lu, 2015, GTP binding and oncogenic mutations may attenuate hypervariable region (HVR)-Catalytic domain interactions in small GTPase K-Ras4B, exposing the effector binding site, J Biol Chem, 290, 28887, 10.1074/jbc.M115.664755 · DOI · Paper page
- Barcelo, 2013, Oncogenic K-ras segregates at spatially distinct plasma membrane signaling platforms according to its phosphorylation status, J Cell Sci, 126, 4553
- Zhou, 2017, Lipid-sorting specificity encoded in K-ras membrane anchor regulates signal output, Cell, 168, 239, 10.1016/j.cell.2016.11.059 · DOI · Paper page
- Zhou, 2021, The KRAS and other prenylated polybasic domain membrane anchors recognize phosphatidylserine acyl chain structure, Proc Natl Acad Sci U S A, 118, 10.1073/pnas.2014605118 · DOI
Cited by
Olivieri, C., Walker, C., Veliparambil Subrahmanian, M., Porcelli, F., Taylor, S. S., Bernlohr, D. A., & Veglia, G. (2023) · FEBS Letters · doi:10.1002/1873-3468.14610 · Cited by 10
Metadata
- Authors
- Abdelkarim, H., Leschinsky, N., Jang, H., Banerjee, A., Nussinov, R., & Gaponenko, V.
- ORCID
- Jang, Hyunbum
- Venue
- Current Opinion in Structural Biology
- Publisher
- Elsevier BV
- Published
- 2021-12
- Volume
- 71
- Pages
- 164-170
- ISSN
- 0959-440X
- Cited by
- 15
- References
- 9
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
- Funders
- Government of South Australia
- National Institutes of Health
- U.S. Department of Health and Human Services
- National Cancer Institute (HHSN261200800001E, R01CA188427)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The dynamic nature of the K-Ras/calmodulin complex can be altered by oncogenic mutations. https://app.cochat.ai/papers/10.1016/j.sbi.2021.06.008
- The paper
- Abdelkarim, H., Leschinsky, N., Jang, H., Banerjee, A., Nussinov, R., & Gaponenko, V. (2021). The dynamic nature of the K-Ras/calmodulin complex can be altered by oncogenic mutations. Current Opinion in Structural Biology. https://doi.org/10.1016/j.sbi.2021.06.008
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.